283 related articles for article (PubMed ID: 12794395)
1. Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial.
Schuster DP; Metzler M; Opal S; Lowry S; Balk R; Abraham E; Levy H; Slotman G; Coyne E; Souza S; Pribble J;
Crit Care Med; 2003 Jun; 31(6):1612-9. PubMed ID: 12794395
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial.
Opal S; Laterre PF; Abraham E; Francois B; Wittebole X; Lowry S; Dhainaut JF; Warren B; Dugernier T; Lopez A; Sanchez M; Demeyer I; Jauregui L; Lorente JA; McGee W; Reinhart K; Kljucar S; Souza S; Pribble J;
Crit Care Med; 2004 Feb; 32(2):332-41. PubMed ID: 14758145
[TBL] [Abstract][Full Text] [Related]
3. Effect of recombinant human platelet-activating factor-acetylhydrolase on allergen-induced asthmatic responses.
Henig NR; Aitken ML; Liu MC; Yu AS; Henderson WR
Am J Respir Crit Care Med; 2000 Aug; 162(2 Pt 1):523-7. PubMed ID: 10934081
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of recombinant platelet-activating factor acetylhydrolase for reducing the incidence and severity of post-ERCP acute pancreatitis.
Sherman S; Alazmi WM; Lehman GA; Geenen JE; Chuttani R; Kozarek RA; Welch WD; Souza S; Pribble J;
Gastrointest Endosc; 2009 Mar; 69(3 Pt 1):462-72. PubMed ID: 19231487
[TBL] [Abstract][Full Text] [Related]
5. Exogenous platelet-activating factor acetylhydrolase reduces mortality in mice with systemic inflammatory response syndrome and sepsis.
Gomes RN; Bozza FA; Amâncio RT; Japiassú AM; Vianna RC; Larangeira AP; Gouvêa JM; Bastos MS; Zimmerman GA; Stafforini DM; Prescott SM; Bozza PT; Castro-Faria-Neto HC
Shock; 2006 Jul; 26(1):41-9. PubMed ID: 16783197
[TBL] [Abstract][Full Text] [Related]
6. Platelet activating factor inhibition in sepsis: the end?
Rabinovici R
Crit Care Med; 2003 Jun; 31(6):1861-2. PubMed ID: 12794432
[No Abstract] [Full Text] [Related]
7. Effect of recombinant platelet-activating factor acetylhydrolase on two models of experimental acute pancreatitis.
Hofbauer B; Saluja AK; Bhatia M; Frossard JL; Lee HS; Bhagat L; Steer ML
Gastroenterology; 1998 Nov; 115(5):1238-47. PubMed ID: 9797380
[TBL] [Abstract][Full Text] [Related]
8. The role of recombinant platelet-activating factor acetylhydrolase in a neonatal rat model of necrotizing enterocolitis.
Caplan MS; Lickerman M; Adler L; Dietsch GN; Yu A
Pediatr Res; 1997 Dec; 42(6):779-83. PubMed ID: 9396557
[TBL] [Abstract][Full Text] [Related]
9. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group.
Dhainaut JF; Tenaillon A; Le Tulzo Y; Schlemmer B; Solet JP; Wolff M; Holzapfel L; Zeni F; Dreyfuss D; Mira JP
Crit Care Med; 1994 Nov; 22(11):1720-8. PubMed ID: 7956274
[TBL] [Abstract][Full Text] [Related]
10. Platelet-activating factor acetylhydrolase is increased in lung lavage fluid from patients with acute respiratory distress syndrome.
Grissom CK; Orme JF; Richer LD; McIntyre TM; Zimmerman GA; Elstad MR
Crit Care Med; 2003 Mar; 31(3):770-5. PubMed ID: 12626982
[TBL] [Abstract][Full Text] [Related]
11. The impact of platelet-activating factor (PAF)-like mediators on the functional activity of neutrophils: anti-inflammatory effects of human PAF-acetylhydrolase.
Kuijpers TW; van den Berg JM; Tool AT; Roos D
Clin Exp Immunol; 2001 Mar; 123(3):412-20. PubMed ID: 11298128
[TBL] [Abstract][Full Text] [Related]
12. Bacterial clearance is improved in septic mice by platelet-activating factor-acetylhydrolase (PAF-AH) administration.
Teixeira-da-Cunha MG; Gomes RN; Roehrs N; Bozza FA; Prescott SM; Stafforini D; Zimmerman GA; Bozza PT; Castro-Faria-Neto HC
PLoS One; 2013; 8(9):e74567. PubMed ID: 24069320
[TBL] [Abstract][Full Text] [Related]
13. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group.
Abraham E; Glauser MP; Butler T; Garbino J; Gelmont D; Laterre PF; Kudsk K; Bruining HA; Otto C; Tobin E; Zwingelstein C; Lesslauer W; Leighton A
JAMA; 1997 May; 277(19):1531-8. PubMed ID: 9153367
[TBL] [Abstract][Full Text] [Related]
14. Plasma platelet-activating factor acetylhydrolase activity in critically ill patients.
Claus RA; Russwurm S; Dohrn B; Bauer M; Lösche W
Crit Care Med; 2005 Jun; 33(6):1416-9. PubMed ID: 15942364
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human platelet-activating factor-acetylhydrolase inhibits airway inflammation and hyperreactivity in mouse asthma model.
Henderson WR; Lu J; Poole KM; Dietsch GN; Chi EY
J Immunol; 2000 Mar; 164(6):3360-7. PubMed ID: 10706731
[TBL] [Abstract][Full Text] [Related]
16. Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis.
Tidswell M; Tillis W; Larosa SP; Lynn M; Wittek AE; Kao R; Wheeler J; Gogate J; Opal SM;
Crit Care Med; 2010 Jan; 38(1):72-83. PubMed ID: 19661804
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human platelet-activating factor acetylhydrolase reduces the frequency of diabetes in the diabetes-prone BB rat.
Lee ES; Jiang J; Sund GC; Simonson WT; Graham J; Dietsch G; Schimpf B; Bieg S; Peterman G; Lernmark A
Diabetes; 1999 Jan; 48(1):43-9. PubMed ID: 9892221
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure.
Abraham E; Naum C; Bandi V; Gervich D; Lowry SF; Wunderink R; Schein RM; Macias W; Skerjanec S; Dmitrienko A; Farid N; Forgue ST; Jiang F
Crit Care Med; 2003 Mar; 31(3):718-28. PubMed ID: 12626975
[TBL] [Abstract][Full Text] [Related]
19. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group.
Dhainaut JF; Tenaillon A; Hemmer M; Damas P; Le Tulzo Y; Radermacher P; Schaller MD; Sollet JP; Wolff M; Holzapfel L; Zeni F; Vedrinne JM; de Vathaire F; Gourlay ML; Guinot P; Mira JP
Crit Care Med; 1998 Dec; 26(12):1963-71. PubMed ID: 9875905
[TBL] [Abstract][Full Text] [Related]
20. Platelet-activating factor inactivator (rPAF-AH) enhances liver's recovery after paracetamol intoxication.
Grypioti AD; Kostopanagiotou G; Mykoniatis M
Dig Dis Sci; 2007 Oct; 52(10):2580-90. PubMed ID: 17410443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
